Physicians' Academy for Cardiovascular Education

The implications of PCSK9 outcome trials for GPs

Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA

PCSK9 Expert Opinions Prof. Richard Hobbs states that recent data from FOURIER show that effective medical treatment to lower LDL-c reduces endpoints that are important and expensive both for individuals and for health systems.

Video navigation menu

  • The most important finding from FOURIER for GPs 01:44
  • Safety profile of evolocumab 03:13
  • Effects on four cognitive function measures met logo EBBINGHAUS 03:48
  • Results with another PCSK9 inhibitor: The SPIRE studies met studies SPIRE 04:48
  • Data reinforcing the importance of effectively treating persons at high secondary risk 06:03

Educational information

This educational video is part of a series of PCSK9 Expert Opinions that are aimed to provide different perspectives and opinions from international experts in this field and may provide support with the interpretation and translation of new findings towards implications for clinical practice

The educational content reflects the personal opinion of the experts and is recorded as an independent educational service by PACE-CME

Disclosures

Prof. Richard Hobbs – University of Oxford, United Kingdom

Funding

Funding was provided by an unrestricted educational grant from Amgen